

University of Illinois Cancer Center Summer CME Series: Hematologic Malignancies June 24, 2026

Fulton Labs
400 N Aberdeen, 16th Floor
Chicago, IL 60642



This activity is jointly provided by Global Education Group (Global) and Shafer Health Strategies.



Target Audience

Medical oncologists, radiation oncologists, surgical oncologists, oncology nurse practitioners, oncology physician assistants, oncology pharmacists, oncology nurses, fellows, residents, and primary care clinicians involved in cancer care.

Statement of Need/Program Overview

This activity is designed to enhance clinicians' ability to diagnose and manage hematologic malignancies and rare cancers, with a focus on recognizing atypical presentations, selecting appropriate diagnostic workups, and applying current treatment algorithms. Emphasis will be placed on conditions that disproportionately affect underserved populations or are frequently under-recognized in community settings.

A second goal is to update learners on rapidly evolving therapeutic landscapes — including targeted agents, immunotherapies, and cellular therapies — while clarifying indications, sequencing considerations, and toxicity mitigation. Faculty will translate complex clinical trial data into practical, real-world decision frameworks.

The final goal is to strengthen interdisciplinary collaboration between oncology, hematology, pathology, pharmacy, and supportive care teams to improve care coordination, reduce preventable complications, and optimize patient outcomes in rare and high-risk malignancies.

Educational Objectives

After completing this activity, the participant should be better able to:

- Review updated clinical evidence and guideline recommendations to treatment sequencing and planning.
- Identify biomarker-driven decision-making into patient management.
- Identify treatment-related toxicities using current best practices.
- Explain how to improve multidisciplinary coordination across oncology specialties.
- Discuss how to address disparities in cancer care affecting hard-to-reach populations.

Series Chair & Presenter

VK Gadi, MD, PhD

Deputy Director, University of Illinois Cancer Center
Assistant Professor of Clinical Medicine, Medical Oncology
UIC Department of Medicine
Chicago, IL

Session Chair & Presenter

Carlos Galvez, MD

UI Health
Chicago, IL

Faculty Presenters

Carlos Murga-Zamalloa, MD

UI Health
Chicago, IL

Jay Vakil, DO

Cook County Health
Chicago, IL

Paul Rubinstein, MD

UI Health
Chicago, IL

Program Agenda

The program agenda can be reviewed [here](#).

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Shafer Health Strategies. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global Education Group designates this live activity for a maximum of *4.0 AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Recognition Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 4.0 MOC point amount medical knowledge MOC in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, participants must achieve a score of 70% or higher on the post-test and complete the final evaluation.

The post-test and evaluation link will be emailed within 1–2 business days following the conclusion of the activity. Please be sure to check your junk or spam folder.

Fee Information & Refund/Cancellation Policy

Please see the fee information [here](#).

Disclosures of Relevant Financial Relationships

Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The **faculty** have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter	Reported Financial Relationship
VK Gadi, MD, PhD	<p>Consulting Fee (e.g., Advisory Board) Puma Biotechnology, Daiichi Sankyo, Novartis, AstraZeneca, Genentech, Bayer, Gilead, Hologic, Lilly, Pfizer</p> <p>Contracted Research (Principal Investigators must provide information, even if received by the institution) Illumina, Novartis, Lilly, Gilead, Agendia, Genentech, Phrontline</p> <p>Stock Shareholder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed) Tempus</p>
Carlos Galvez, MD	Nothing to Disclose
Carlos Murga-Zamalloa, MD	Nothing to Disclose
Jay Vakil, DO	Nothing to Disclose
Paul Rubinstein, MD	Nothing to Disclose

The **planners and managers** have the following relevant financial relationships with ineligible companies: The planners and managers at Global Education Group and Shafer Health Strategies have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Shafer Health Strategies do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.